Prime Medicine, Inc.
NASDAQPrime Medicine enters the week with an uncomfortable combination: a fresh analyst endorsement pointing to significant upside, a short base near its highest level of the year, and a borrow market that just tightened sharply — all while the stock slips to $3.05, down 6.4% on the week. The lending market tells a striking story this week. Borrow availability collapsed to 8.9% — meaning…
PRME utilization hits 94.93%, near 52-week peak of 99.93%, as short sellers lock in scarce borrowed shares amid 18.9% short interest in the gene-editing biotech.
Snapshot as of 26 Aug 2026
Prime Medicine enters the week with an uncomfortable combination: a fresh analyst endorsement pointing to significant upside, a short base near its highest level of the year, and a borrow market that just tightened…
Prime Medicine enters the week in an unusual spot for a heavily shorted biotech — the stock is up 8% on the week and 30% over the past month, while bears have been quietly adding to already elevated positions. The…
PRME heads into its June 5 earnings call with short positioning at its most crowded level in months and the borrow market tightening sharply — a setup that puts maximum pressure on whatever the company delivers next…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for PRME — free to start on ORTEX.
Sign up for free →Open PRME on ORTEX